6533b82efe1ef96bd12934bd
RESEARCH PRODUCT
Presepsin and Midregional Proadrenomedullin in Pediatric Oncologic Patients with Febrile Neutropenia
Marcello CiaccioElisa ParisiGiulia BivonaLuisa AgnelloAnna Maria CiaccioGiuseppe Dejan LucidoOttavio ZiinoAlessandro IaconaRosaria Vincenza Gigliosubject
Malemedicine.medical_specialtymedicine.medical_treatmentpediatric.Clinical BiochemistryLipopolysaccharide ReceptorsNeutropeniaAdrenomedullinmr-proADMmalignancieNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansneutropeniaMedicineBlood cultureProtein PrecursorsFever of unknown originChildFebrile NeutropeniafeverChemotherapymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPresepsinBiochemistry (medical)Age FactorsPrognosismedicine.diseasePeptide FragmentsAdrenomedullinROC CurveoncologicBacteremiaFemalebusinessBiomarkersFebrile neutropeniadescription
Abstract Objective In this study, we investigated the roles of presepsin (PSP) and midregional proadrenomedullin (mr-proADM) in children with febrile neutropenia (FN) due to chemotherapy. Methods We assessed 36 FN episodes in 26 children. Patients were classified into bacteremia (B) and fever of unknown origin (FUO) groups. We evaluated PSP and mr-proADM at admission (T0), after 24/48 h (T1), and after 5 days (T2). Results PSP and mr-proADM levels were elevated at T0 and significantly decreased at T2. mr-proADM levels did not significantly differ between the B and FUO groups. PSP levels significantly differed between the B and FUO groups only at T1. Both PSP and mr-proADM levels at T0 were a predictor of length of hospital stay but not of the duration of fever. Finally, receiver operating characteristic curve analysis showed that PSP and mr-proADM had low diagnostic accuracy for blood culture positivity. Conclusion PSP and mr-proADM display poor clinical usefulness for FN in oncologic children.
year | journal | country | edition | language |
---|---|---|---|---|
2020-03-28 | Laboratory Medicine |